Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies (confirmed biallelic RPE65 gene mutations)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency (ADA–SCID)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 (CLN2) in children
Evidence-based decisions on Endocuff Vision for assisting visualisation during colonoscopy
Evidence-based recommendations on the moorLDI2-BI a laser doppler blood flow imager for burn wound assessment
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds
Evidence-based recommendations on the Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters
Evidence-based recommendations on PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites
Evidence-based recommendations on ENDURALIFE-powered cardiac resynchronisation therapy-defibrillator (CRT-D) devices for treating heart failure
Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed
Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery
Evidence-based recommendations on the Ambu aScope4 Broncho for use in unexpected difficult airways
Evidence-based recommendations on SecurAcath for securing percutaneous catheters (central venous catheters/CVCs)
Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia in patients having abdominal surgery
Evidence-based recommendations on the EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing
Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms
Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers
Evidence-based recommendations on the 3M Tegaderm CHG IV securement dressing for central venous and arterial catheter insertion sites
Evidence-based recommendations on Thopaz+ for people who need chest drainage after a pulmonary resection or because of a collapsed lung
Evidence-based recommendations on Memokath-051 stent for treating ureteric obstruction
Evidence-based recommendations on iFuse titanium implant joint fusion system for treating chronic sacroiliac (SI) joint pain (lower back pain)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy (nerve damage) by detecting inadequate sweat production
Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions
Evidence-based recommendations on gammaCore for cluster headache
Evidence-based recommendations on Curos for preventing infections when using needleless connectors
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain
Evidence-based recommendations on the Peristeen transanal irrigation system for people with bowel dysfunction
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma
NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma
NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults
NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was
NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was
NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from
NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the
NICE is unable to make a recommendation about the use in the NHS of afatinib for advanced squamous non-small-cell lung cancer after platinum-based chemotherapy